Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs von Felip, E., Shaw, A.T., Bearz, A., Camidge, D.R., Solomon, B.J., Bauman, J.R., Bauer, T.M., Peters, S., Toffalorio, F., Abbattista, A., Thurm, H., Peltz, G., Wiltshire, R., Besse, B.

Volltext

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study von Joensuu, H, De Braud, F, Grignagni, G, De Pas, T, Spitalieri, G, Coco, P, Spreafico, C, Boselli, S, Toffalorio, F, Bono, P, Jalava, T, Kappeler, C, Aglietta, M, Laurent, D, Casali, P G

Volltext

Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids von Toffalorio, F, Belloni, E, Barberis, M, Bucci, G, Tizzoni, L, Pruneri, G, Fumagalli, C, Spitaleri, G, Catania, C, Melotti, F, Pelicci, P G, Spaggiari, L, De Pas, T

Volltext

The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study von Catania, C., Radice, D., Spitaleri, G., Adamoli, L., Noberasco, C., Delmonte, A., Vecchio, F., de Braud, F., Toffalorio, F., Goldhirsch, A., De Pas, T.

Volltext

1360P Updated patient-reported outcomes from the CROWN study: Analyses in first-line ALK+ patients with (w) and without (w/o) baseline brain metastases (BMs) and w or w/o central n... von Liu, G., Zhou, Q., Solomon, B.J., Le, H., Reisman, A., Thomaidou, D., Toffalorio, F., Mazieres, J.

Volltext

The use of Raman spectroscopy to identify inorganic phases in iatrogenic pathological lesions of patients with malignant pleural mesothelioma von Musa, M., Croce, A., Allegrina, M., Rinaudo, C., Belluso, E., Bellis, D., Toffalorio, F., Veronesi, G.

Volltext

Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer von Toffalorio, F, Giovannetti, E, De Pas, T, Radice, D, Pelosi, G, Manzotti, M, Minocci, D, Spaggiari, L, Spitaleri, G, Noberasco, C, Catania, C, Boselli, S, Danesi, R, de Braud, F

Volltext

1008P Resistance mechanisms to lorlatinib or crizotinib in treatment-naive patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) von Felip, E., Martini, J-F., Mazieres, J., Kim, D-W., Shepard, D., Polli, A., Liu, G., de Marinis, F., Toffalorio, F., Goto, Y., Solomon, B.

Volltext

Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration von De Pas, T.M., Toffalorio, F., Catania, C., Noberasco, C., Spitaleri, G., Spaggiari, L., De Braud, F.

Volltext

1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression von Ou, S.I., Solomon, B., Shaw, A., Gadgeel, S.M., Besse, B., Soo, R.A., Abbattista, A., Thurm, H., Toffalorio, F., Wiltshire, R.J., Bearz, A.

Volltext

1196P Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) von Solomon, B.J., Martini, J-F., Bearz, A., Tan, E.H., Soo, R., Besse, B., Bauer, T.M., Shepard, D., Toffalorio, F., Abbattista, A., Felip, E., Shaw, A.T., Viteri, S., Camidge, D.R., Seto, T., Ou, S-H.I.

Volltext

P84.09 Asian Subgroup Analysis of a Phase II Study Evaluating Lorlatinib Efficacy in Previously Treated ALK-Positive Advanced NSCLC von Soo, R., Lin, C., Kim, D., Seto, T., Tan, E., Hayashi, H., Abbattista, A., Martini, J., Wong, C.H., Toffalorio, F., Solomon, B.

Volltext

1487PDIntracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting von Camidge, D R, Solomon, B J, Felip, E, Besse, B, Bearz, A, Peters, S, Toffalorio, F, Abbattista, A, Thurm, H, Peltz, G, Wiltshire, R, Shaw, A T

Volltext

1487PD - Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting von Camidge, D.R., Solomon, B.J., Felip, E., Besse, B., Bearz, A., Peters, S., Toffalorio, F., Abbattista, A., Thurm, H., Peltz, G., Wiltshire, R., Shaw, A.T.

Volltext

Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting von Camidge, D.R., Solomon, B.J., Felip, E., Besse, B., Bearz, A., Peters, S., Toffalorio, F., Abbattista, A., Thurm, H., Peltz, G., Wiltshire, R., Shaw, A.T.

Volltext

A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma von Catania, C, Pelosi, G, Fazio, N, Biffi, R, Spitaleri, G, Noberasco, C, Zampino, MG, Maggioni, A, Trifirò, G, Toffalorio, F, Vigna, P Della, De Braud, F, De Pas, T

Volltext

Optimizing Clinical Care in Patients with Advanced Soft Tissue Sarcoma: A Phase II Study of a New Schedule of High-Dose Continuous Infusion Ifosfamide and Doxorubicin Combination von De Pas, T., Rosati, G., Spitaleri, G., Boni, C., Tucci, A., Frustaci, S., Scalamogna, R., Radice, D., Boselli, S., Toffalorio, F., Catania, C., Noberasco, C., Delmonte, A., Vecchio, F., de Braud, F.

Volltext

Safety of lorlatinib in subgroups of patients from a phase I/II trial von Felip, E., Solomon, B.J., Besse, B., Bauer, T.M., Soo, R.A., Camidge, D.R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S.M., Tan, E.-H., Seto, T., Oxnard, G.R., Peltz, G., Abbattista, A., Thurm, H., Toffalorio, F., Ou, S-H I, Shaw, A.T.

Volltext

1542PSafety of lorlatinib in subgroups of patients from a phase I/II trial von Felip, E, Solomon, B J, Besse, B, Bauer, T M, Soo, R A, Camidge, D R, Chiari, R, Bearz, A, Lin, C-C, Gadgeel, S M, Tan, E-H, Seto, T, Oxnard, G R, Peltz, G, Abbattista, A, Thurm, H, Toffalorio, F, Ou, S-H I, Shaw, A T

Volltext

1542P - Safety of lorlatinib in subgroups of patients from a phase I/II trial von Felip, E., Solomon, B.J., Besse, B., Bauer, T.M., Soo, R.A., Camidge, D.R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S.M., Tan, E.-H., Seto, T., Oxnard, G.R., Peltz, G., Abbattista, A., Thurm, H., Toffalorio, F., Ou, S-H I, Shaw, A.T.

Volltext